BioSpace News Archive

Advancium Health Network and Silicon Valley Bank to Launch Not-For-Profit Cure Innovation Labs ℠ Accelerating Early Stage Life Science Companies.

EarliTec Dx, Inc. announced today a $19.5 million financing to further its mission of making earlier ASD identification and treatment accessible to children everywhere.

Moderna, Inc. today announced that it is expanding its mRNA pipeline with three new development programs.

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, will present at the Biocom Global Life Science Partnering Conference in San Diego on Thursday, February 24, 2022.

The Nomination Committee prior to the 2022 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2021, and the Chairman of the Board.

TransThera Sciences (Nanjing), Inc. (“TransThera”) announced that the U.S. Food and Drug Administration (“FDA”) approved the Investigational New Drug (“IND”) application of TT-01488, a non-covalent reversible Bruton’s Tyrosine Kinase (“BTK”) inhibitor, for the treatment of B-cell lymphomas on January 24, 2022, and TransThera will initiate the Phase I clinical trials in the U.S. soon.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 2b QUASAR Induction Study 1.

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new results from the Phase 2 GALAXI 1 clinical trial showing the majority (57.4-73 percent) of adults with moderately to severely active Crohn’s disease (CD) who were treated with TREMFYA® (guselkumab) achieved clinical remission (Crohn’s Disease Activity Index [CDAI]<150)a at week 48.

The board of directors of Abbott declared a quarterly common dividend of 47 cents per share.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19.